Oncotype DX検査は


Oncotype DX®検査は臨床経験情報を提供します:


Japan Stage

患者選択上の考慮点は、NSABP B-14、NSABP B-20、TransATAC、およびSWOG 88141-4といった一連のOncotype DX試験からのデータに基づいています。

Oncotype DX検査は、化学療法の効果を予測するものとして4つの主要臨床ガイドラインに採用されている唯一の多遺伝子乳癌検査です5-7


1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer. J Clin Oncol. 2006;24:3726-3734.
2. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
3. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene Recurrence Score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study. J Clin Oncol. 2010;28:1829-1834.
4. Albain K, Barlow W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55-65.
5. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology™: Breast cancer. Version 3.2013. Available at: www.nccn.org.
6. Harris L, Fritsche H, Mennel R, et al. American Journal of Clinical Oncology 2007 update of recommendations; 33(25):5287-5312
7. Goldhirsch A, Winer E.P., Coates A, Gelber R.D., Piccart-Gebhart M.,Thürlimann B., Senn H-J, and Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.Ann Oncol 2013; 24(9):2206-23
8. Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 (suppl 6); vi7-vi23

European Society of Medical Oncology (ESMO) [欧州臨床腫瘍学会(ESMO)]およびESMOはESMOの商標です。American Society of Clinical Oncology (ASCO) [アメリカ臨床腫瘍学会(ASCO)]およびASCOはASCOの登録商標で、National Comprehensive Cancer Network (NCCN) [全米総合癌情報ネットワーク(NCCN)]およびNCCNはNCCNの登録商標です。ESMO、St. Gallen、ASCOおよびNCCNは、いかなる治療用製品も支持するものではありません。







Making cancer care smarter.™